Reliable high risk HPV DNA testing by polymerase chain reaction: an intermethod and intramethod comparison

被引:67
作者
Jacobs, MV
Snijders, PJF
Voorhorst, FJ
Dillner, J
Forslund, O
Johansson, B
Doeberitz, MVK
Meijer, CJLM
Meyer, T
Nindl, I
Pfister, H
Stockfleth, E
Strand, A
Wadell, G
Walboomers, JMM
机构
[1] Vrije Univ Amsterdam Hosp, Dept Pathol, Sect Mol Pathol, NL-1081 HV Amsterdam, Netherlands
[2] Vrije Univ Amsterdam Hosp, Dept Epidemiol & Biostat, Amsterdam, Netherlands
[3] Karolinska Inst, Microbiol & Tumour Biol Ctr, Stockholm, Sweden
[4] Lund Univ, Gen Hosp, Sect Virol, Malmo, Sweden
[5] Huddinge Univ Hosp, Karolinska Inst, Dept Immunol Microbiol Pathol & Infect Dis, S-14186 Huddinge, Sweden
[6] Heidelberg Univ, Surg Clin, Sect Mol Diagnosis & Therapy, Heidelberg, Germany
[7] Inst Immunol Pathol & Mol Biol, Hamburg, Germany
关键词
human papillomavirus; polymerase chain reaction; intermethod agreement; intramethod agreement;
D O I
10.1136/jcp.52.7.498
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Background-The development of a reproducible, sensitive, and standardised human papillomavirus (HPV) polymerase chain reaction (PCR) test is required to implement HPV testing in cervical cancer screening programmes and for triaging women with mild to moderate dysplasia. Aims-To determine the intermethod agreement between different GP5+/6+ and MY09/11 PCR based protocols for the detection and typing of high risk (HR) HPV DNA in cervical smears and to assess the intramethod reproducibility of the GP5+/6+ PCR enzyme immunoassay (ELA) for HR-HPV detection. Methods-For the intermethod comparison, crude aliquots of 20 well characterised cervical smears comprising five HPV negative samples, and six and nine samples containing single and multiple HPV infections, respectively were coded and sent from reference laboratory (A) to three other laboratories. One of these (laboratory B) used the GP5+/6+ PCR-EIA and was provided with standard protocols. Another laboratory (C) used GP5+/6+ PCR combined with sequence analysis and type specific PCR, whereas two laboratories (D and E) used MY09/11 PCR followed by restriction fragment length polymorphism (RFLP) analysis for the detection and typing of HR-HPV. The intramethod agreement of GP5+/6+ PCR-EIA was analysed in a subsequent study with four other laboratories (F to I) on crude aliquots of 50 well characterised cervical smears, consisting of 32 HR-HPV positive and 18 HPV negative samples. Standardised protocols, primers, and probes were also provided by the reference laboratory for HR-HPV detection. Results-In the intermethod comparison, pairwise agreement of the different laboratories with reference laboratory A for the detection of HR-HPV varied between 75% and 100% (kappa values: 0.5 to 1). Typing data revealed a broader range in pairwise agreement rates between 32% and 100%. The highest agreement was found between laboratories A and B using standardised protocols and validated reagents. In the intramethod evaluation, pairwise comparison of the laboratories F to I with reference laboratory A revealed excellent agreement rates from 92% to 100% (kappa values: 0.88 to 1.0) with an overall sensitivity of 97.5% (195/200) and specificity of 99.5% (199/200). Conclusions-The detection of HR-HPV as a group is highly reproducible with GP5+/6+ PCR-EIA provided that standardised protocols and validated reagents are used.
引用
收藏
页码:498 / 503
页数:6
相关论文
共 32 条
  • [1] Risk factors for cervical cancer in Thailand:: A case-control study
    Chichareon, S
    Herrero, R
    Muñoz, N
    Bosch, FX
    Jacobs, MV
    Deacon, J
    Santamaria, M
    Chongsuvivatwong, V
    Meijer, CJLM
    Walboomers, JMM
    [J]. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1998, 90 (01) : 50 - 57
  • [2] HUMAN PAPILLOMAVIRUS TESTING BY HYBRID CAPTURE APPEARS TO BE USEFUL IN TRIAGING WOMEN WITH A CYTOLOGIC DIAGNOSIS OF ATYPICAL SQUAMOUS CELLS OF UNDETERMINED SIGNIFICANCE
    COX, JT
    LORINCZ, AT
    SCHIFFMAN, MH
    SHERMAN, ME
    CULLEN, A
    KURMAN, RJ
    [J]. AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1995, 172 (03) : 946 - 954
  • [3] HUMAN PAPILLOMAVIRUS TESTING IN PRIMARY CERVICAL SCREENING
    CUZICK, J
    SZAREWSKI, A
    TERRY, G
    HO, L
    HANBY, A
    MADDOX, P
    ANDERSON, M
    KOCJAN, G
    STEELE, ST
    GUILLEBAUD, J
    [J]. LANCET, 1995, 345 (8964) : 1533 - 1536
  • [4] DEVESA SS, 1989, CANCER, V64, P2184, DOI 10.1002/1097-0142(19891115)64:10<2184::AID-CNCR2820641034>3.0.CO
  • [5] 2-8
  • [6] Fleiss JL, 1981, STAT METHODS RATES P
  • [7] Giard R W, 1992, Ned Tijdschr Geneeskd, V136, P2311
  • [8] AN EVALUATION OF HUMAN PAPILLOMAVIRUS TESTING FOR INTERMEDIATE-RISK AND HIGH-RISK TYPES AS TRIAGE BEFORE COLPOSCOPY
    HATCH, KD
    SCHNEIDER, A
    ABDELNOUR, MW
    [J]. AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1995, 172 (04) : 1150 - 1157
  • [9] Hsing AW, 1996, CANCER EPIDEM BIOMAR, V5, P483
  • [10] PROCESSING OF LONG-STORED ARCHIVAL CERVICAL SMEARS FOR HUMAN PAPILLOMAVIRUS DETECTION BY THE POLYMERASE CHAIN-REACTION
    HUSMAN, AMD
    SNIJDERS, PJF
    STEL, HV
    VANDENBRULE, AJC
    MEIJER, CJLM
    WALBOOMERS, JMM
    [J]. BRITISH JOURNAL OF CANCER, 1995, 72 (02) : 412 - 417